A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases.
Learn MoreJoin us in creating the future of eye care!
Our Products
We currently market two innovative prescription eye drops for lowering intraocular pressure (IOP) in glaucoma.
Learn More
Our Research
We are making significant progress in developing new treatments for dry eye and retinal diseases.
Learn More
STOCK Quote
NASDAQ: AERI
$15.25USD
Nov 18, 4:00 PM ET
Latest News
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
DISCOVaerie™ Live!
Visit our virtual destination for the eye care community to get informed and connected.
MORE
CAREERS AT AERIE
We are looking for VISIONaerieS® who share our passion for innovation to protect sight.
MORE
OUR ESG COMMITMENT
Aerie is dedicated to environmental stewardship, social responsibility, and good corporate governance.
MORE